Clinical trials: Adolescent HPV Vaccine
Cervical Cancer, Genital Warts
Study of an Investigational Vaccine in Pre-Adolescents and Adolescents (Gardasil)(V501-016)
The primary purpose of the study is to determine if an investigational vaccine Gardasil (V501) with 4 components will provide an immune response and will be well tolerated in pre-adolescents and adolescents.
- Trial name
- NCT00092495
- Testing
- V501, Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine
- Volunteers
- 3,055 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
HPV Infection, Preventive Health Services
PCOM2 - The Physician Communication Intervention, Version 2.0
Poor quality of primary care providers' vaccine recommendations lead to low adolescent human papillomavirus vaccination rates and hundreds of thousands of adolescents unnecessarily at risk for HPV-associated cancers and diseases.
- Trial name
- PCOM2 (NCT05336240)
- Testing
- Physician Communication 2 Virtual (PCOM2-virtual), Physician Communication Standard (PCOM-standard)
- Where
- 2 sites in United States
- Volunteers
- 120 people
- Sponsor
- University of Colorado, Denver
HPV Vaccination, Uptake Vaccination
PREVENT Pilot HPV - Related Cancers Trial
This study will serve as one of the first to develop and test the effectiveness of strategies to promote HPV vaccination among diverse rural parents and caregivers of children ages 9-17 years in the Mountain West.
- Conditions
- HPV Vaccination, Uptake Vaccination, Series Completion
- Trial name
- NCT06738355
- Testing
- PREVENT
- Where
- United States
- Volunteers
- 335 people, healthy volunteers welcome
- Sponsor
- University of Utah
Human Papillomavirus Vaccination
HPV Vaccine Reminders - SEARCH II Study
This RCT will take place at health centres and their affiliated schools and community immunization centers overseen by the Kampala Capital City Authority (KCCA) as well as at the Makerere/Mulago/Columbia Adolescent Health Clinic…
- Trial name
- NCT06161831
- Testing
- Text Message/automated phone reminder
- Where
- 2 sites in United States, Uganda
- Volunteers
- 396 people
- Sponsor
- Columbia University
Papillomavirus Vaccines, HPV Vaccines
HPV Vaccine Integrated Service Implementation Research in Ethiopia
The goal of this implementation research study is to understand whether a package of community-based interventions can increase access to and uptake of the human papillomavirus (HPV) vaccine among very young adolescent girls in…
- Conditions
- Papillomavirus Vaccines, HPV Vaccines, HPV Vaccine Acceptability, HPV Vaccine Attitudes
- Trial name
- HPV-VISION (NCT06667323)
- Testing
- Integrated health service delivery for very young adolescent girls
- Volunteers
- 1,140 people, healthy volunteers welcome
- Sponsor
- Population Services International
Human Papillomavirus
Interactive, Health Literacy Promoting Text Messages and HPV Vaccine Completion In Minority Adolescents
Emerging communication technologies, such as text messaging offer low-cost, scalable opportunities to improve health literacy and promote healthy behaviors, such as vaccination.
- Trial name
- NCT02236273
- Testing
- Conventional text message reminder, Enhanced text message reminders
- Where
- United States
- Volunteers
- 956 people
- Sponsor
- Columbia University
Papillomavirus Vaccines
Impact of Adolescent Vaccine Reminder Notices Sent Via Preferred Method of Communication on HPV Vaccination
Vaccine uptake in the United States is lower in rural areas, especially for HPV vaccine. Reminder/recall has been identified as an effective strategy to increase vaccination rates.
- Trial name
- NCT05148559
- Testing
- Reminder Sent Via Preferred Method of Communication, Reminder Sent Via Mailed Letter
- Where
- United States
- Volunteers
- 5,451 people
- Sponsor
- Huong Nguyen, PhD
Infections, Papillomavirus
Evaluation of Safety and Immunogenicity of Co-administering Human Papillomavirus Vaccine With Another Vaccine in Healthy Female Subjects
Infection with human papillomavirus (HPV) has been clearly established as the central cause of cervical cancer. Vaccination of pre-teens and adolescents, ideally before sexual debut and thus before exposure to oncogenic HPV, is a…
- Trial name
- NCT00578227
- Testing
- Cervarix™, Twinrix ™ Paediatric
- Where
- 21 sites in Canada, Denmark and 2 more
- Volunteers
- 814 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Human Papillomavirus Vaccines, Adolescent Health Services
HPV Vaccine Communication ECHO for Primary Care Clinics
The safe, highly-effective human papillomavirus (HPV) vaccine remains underused in the US; only 51% of 13- to 17-year-old girls and boys were up-to-date by 2018.
- Trial name
- NCT04587167
- Testing
- Project ECHO, Announcement Approach Training, Recall notices
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Milton S. Hershey Medical Center
Human Papilloma Virus
A Multilevel Approach to Increasing HPV Vaccine Initiation Among Adolescents - Part 3
Our project will assess the feasibility and estimate preliminary efficacy of a multilevel intervention to improve HPV vaccine series initiation among adolescents in Medicaid and CHIP.
- Trial name
- NCT04208269
- Testing
- postcard campaign, Health Information Technology system
- Where
- United States
- Volunteers
- 5,663 people, healthy volunteers welcome
- Sponsor
- University of Florida
HPV Vaccine Acceptability
Impact of a School- and Primary Care-based Multicomponent Intervention on HPV Vaccination Acceptability
This study aims at evaluating the effectiveness, efficiency and implementation of a multicomponent intervention (components being applied in combination or alone) on the acceptability of HPV vaccine among French adolescents…
- Trial name
- PrevHPV (NCT04945655)
- Testing
- Adolescents and parents' education and motivation at school (component 1), General practitioners' training (component 2), Access to vaccination at school (component 3)
- Where
- France
- Volunteers
- 30,739 people, healthy volunteers welcome
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Cervical Intraepithelial Neoplasia, Papillomavirus Infection
Human Papilloma Virus (HPV) Vaccine Trial in Young Adolescent Women With GlaxoSmithKline Biologicals' (GSK Bio) HPV-16/18 Vaccine
This protocol posting deals with objectives \& outcome measures of the extension phase up to Month 48. The objective of the extension study is to evaluate the long-term immunogenicity of the HPV 16/18 L1 VLP AS04 vaccine (for all…
- Trial name
- NCT00316706
- Testing
- GSK Biologicals' HPV-16/18 Vaccine (Cervarix™), Havrix™
- Where
- 28 sites in Colombia, Germany and 3 more
- Volunteers
- 1,245 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Human Papillomavirus Virus
Observational Follow up of Prior HPV Vaccinees
HPV vaccines have been included in the national immunisation schedule since 2008, firstly as the Cervarix vaccine which protects against two HPV types and in 2012 as the Gardasil vaccine which offers protection against a further…
- Trial name
- HPVfollowup (NCT02811068)
- Testing
- venepuncture
- Where
- 2 sites in United Kingdom
- Volunteers
- 93 people, healthy volunteers welcome
- Sponsor
- Public Health England
Human Papilloma Virus (HPV), Tetanus-diphtheria-acellular Pertussis (Tdap)
Evaluation of Vaccination Reminder/Recall Systems for Adolescent Patients
A study team with extensive experience in immunization delivery research will evaluate the effectiveness of vaccination reminder/recall systems for adolescent patients in five types of clinical settings including: urban…
- Conditions
- Human Papilloma Virus (HPV), Tetanus-diphtheria-acellular Pertussis (Tdap), Meningococcal Infection, Varicella
- Trial name
- NCT00715234
- Testing
- Reminder/recall notices for vaccines
- Volunteers
- 4,807 people
- Sponsor
- University of Colorado, Denver
Infections, Papillomavirus
Effectiveness, Safety and Immunogenicity of GSK Biologicals' HPV Vaccine GSK580299 (Cervarix) Administered in Healthy Adolescents
Genital infections with oncogenic human papillomaviruses (HPV) are common in both men and women. The most important disease associated with oncogenic HPV infection is cervical cancer, currently the second leading cause of…
- Trial name
- NCT00534638
- Testing
- Cervarix, Engerix-B
- Where
- 6 sites in Finland
- Volunteers
- 34,412 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Cervical Cancer
Health Care Decisions for Female Adolescents: The Role of Mothers and Daughters in Decision Making
Preventing cervical cancer is a public health concern. Since 2006 a quadrivalent vaccine for young women nine to twenty six years of age has been available to protect against the human papillomavirus (HPV) and to prevent some…
- Trial name
- NCT00807898
- Where
- United States
- Volunteers
- 136 people, healthy volunteers welcome
- Sponsor
- University of Louisville
Completion of Three Dose Series of HPV, Improvement in Vaccine Intervals Between HPV Doses
The Efficacy of Reminders to Complete HPV Series
The human papillomavirus (HPV) vaccine is routinely recommended for both adolescent girls and boys starting at age 11, although it can be offered as young as 9 years of age.
- Trial name
- ICHAT (NCT01731496)
- Testing
- Telephone reminder, Text Message reminder
- Where
- 3 sites in United States
- Volunteers
- 749 people, healthy volunteers welcome
- Sponsor
- University of Rochester
Health Education
The Effects of Health Education About Human Papilloma Virus and Cervical Cancer Prevention on Knowledge, Attitudes, Beliefs and Behaviors
Aim: To determine the effects of health education about Human Papilloma Virus infection and cervical cancer prevention on knowledge, attitudes, beliefs and behaviors of adolescent girls and their mothers.
- Trial name
- NCT04113902
- Testing
- Health Education
- Where
- Turkey (Türkiye)
- Volunteers
- 216 people, healthy volunteers welcome
- Sponsor
- Saglik Bilimleri Universitesi Gulhane Tip Fakultesi
Human Papillomavirus Infection
A Phase III Study of a 2-dose Regimen of a Multivalent Human Papillomavirus (HPV) Vaccine (V503), Administered to 9 to 14 Year-olds and Compared to Young Women, 16 to 26 Years Old (V503-010)
This was a 37-month safety and immunogenicity study conducted in boys and girls 9 to 14 years of age and in young women 16 to 26 years of age.
- Trial name
- NCT01984697
- Testing
- V503 (9-valent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] vaccine)
- Volunteers
- 1,518 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Human Papillomavirus, Cervix Cancer
Prevention of HPV in the School Health Service
The last ten years sexually transmitted infections (STI) have substantially increased among adolescents. STI can lead to individual suffering and have a negative effect on the future reproductive health and also increase the need…
- Trial name
- NCT02280967
- Testing
- Education about HPV by school nurse
- Where
- Sweden
- Volunteers
- 832 people, healthy volunteers welcome
- Sponsor
- Uppsala University